Hsu T C, Nair R, Tulsian P, Camalier C E, Hegamyer G A, Young M R, Colburn N H
Frederick Cancer Research and Development Center, National Cancer Institute, Frederick, MD 21702, USA.
Cancer Res. 2001 May 15;61(10):4160-8.
Clonal variants of mouse epidermal JB6 cells that are genetically susceptible (P+) or resistant (P-) to tumor promoter-induced neoplastic transformation exhibit differential activator protein-1 (AP-1) response. Transactivation of AP-1 appears to be necessary but not sufficient to promote transformation in JB6 cells. Inhibition of AP-1 is invariably accompanied by inhibition of nuclear factor-kappaB (NF-kappaB) when transformation is suppressed, suggesting that NF-kappaB may also play a role in neoplastic transformation. We report here that transactivation of NF-kappaB is inducible by tumor promoters in P+ but not in P- JB6 cells. Inhibition of NF-kappaB using a nondegradable mutant of IkappaBalpha suppressed inducible anchorage-independent transformation of P+ JB6 cells, suggesting that NF-kappaB activation is required for tumor promotion. Induced degradation of IkappaBalpha occurred in both P+ and P- JB6 cells, indicating that failure to activate NF-kappaB in P- JB6 cells cannot be attributed to failure to degrade IkappaBalpha. Slightly higher levels of nuclear p65 were seen in P+ than in P- JB6 cells. The p65-specific DNA binding activity was also higher in P+ cells upon induction by tumor necrosis factor-alpha, suggesting that differential NF-kappaB activation may be attributable to changes in p65 activity. Transactivation of p65 protein was substantially higher in P+ than in P- JB6 cells, as determined by assay of Gal4-p65 fusion constructs. Thus activated, p65 may be a limiting factor for NF-kappaB activation and transformation responses. Stable expression of p65 in P- JB6 cells conferred not only inducible NF-kappaB and AP-1 activation but also transformation response to tumor promoters. Therefore, p65/NF-kappaB appears to be not only necessary for but also sufficient to confer tumor promotion response. Although stable expression of p65 in P- cells produced p65 increases in whole cell extracts, only the transfectants exhibiting increased nuclear p65 showed transformation response. Thus, elevation of nuclear p65 appears to be a necessary step for a transformation response. The P-/p65 transfectants showing acquired transformation response also showed elevated p65-specific transactivation response, thus recapitulating the NF-kappaB phenotypes seen in P+ cells. Expression of a transactivation-deficient mutant of Jun or dominant-negative extracellular signal-regulated kinase suppressed both AP-1 activation and p65-specific transactivation in JB6 cells, suggesting that AP-1 activity is needed for p65 transactivation and consequently for NF-kappaB activation. Thus, the transformation nonresponsive P- JB6 cells owe their resistance to lack of NF-kappaB activation and p65 transactivation that appears in turn to be attributable to insufficient AP-1 activation.
对肿瘤启动子诱导的肿瘤转化具有遗传易感性(P+)或抗性(P-)的小鼠表皮JB6细胞克隆变体表现出不同的活化蛋白-1(AP-1)反应。AP-1的反式激活似乎是促进JB6细胞转化所必需的,但并不充分。当转化受到抑制时,AP-1的抑制总是伴随着核因子-κB(NF-κB)的抑制,这表明NF-κB可能也在肿瘤转化中起作用。我们在此报告,NF-κB的反式激活在P+而非P- JB6细胞中可被肿瘤启动子诱导。使用IκBα的不可降解突变体抑制NF-κB可抑制P+ JB6细胞的诱导性锚定非依赖性转化,这表明NF-κB激活是肿瘤促进所必需的。IκBα的诱导性降解在P+和P- JB6细胞中均发生,这表明P- JB6细胞中未能激活NF-κB不能归因于未能降解IκBα。在P+ JB6细胞中观察到的核p65水平略高于P- JB6细胞。在肿瘤坏死因子-α诱导后,P+细胞中的p65特异性DNA结合活性也更高,这表明NF-κB的差异激活可能归因于p65活性的变化。通过检测Gal4-p65融合构建体确定,P+ JB6细胞中p65蛋白的反式激活明显高于P- JB6细胞。如此被激活后,p65可能是NF-κB激活和转化反应的限制因素。p65在P- JB6细胞中的稳定表达不仅赋予了诱导性NF-κB和AP-1激活,还赋予了对肿瘤启动子的转化反应。因此,p65/NF-κB似乎不仅是赋予肿瘤促进反应所必需的,也是充分的。尽管p65在P-细胞中的稳定表达导致全细胞提取物中p65增加,但只有核p65增加的转染子表现出转化反应。因此,核p65的升高似乎是转化反应的必要步骤。显示获得性转化反应的P-/p65转染子也显示出p65特异性反式激活反应升高,从而重现了P+细胞中所见的NF-κB表型。Jun的反式激活缺陷突变体或显性负性细胞外信号调节激酶的表达抑制了JB6细胞中的AP-1激活和p65特异性反式激活,这表明AP-1活性是p65反式激活所必需的,因此也是NF-κB激活所必需的。因此,对转化无反应的P- JB6细胞的抗性归因于缺乏NF-κB激活和p65反式激活,而这反过来又似乎归因于AP-1激活不足。